Scientists Develop Eye Drops that Dissolve Cataracts

pharmanewsonline | May 14, 2019

Scientists Develop Eye Drops that Dissolve Cataracts
Researchers from the University of California, San Diego, have developed a new drug that can be administered directly into the eye through an eye dropper to shrink and dissolve cataracts – the leading cause of blindness in humans. While the effects are yet to be tested on humans, the team hopes to replicate the findings in clinical trials and offer an alternative to the only treatment that is currently available to cataract patients, which is painful and often prohibitively expensive surgery. According to the result published in a journal Pubmed, It has been estimated that cataractaccounted for 47.8 percent of the 37 million people who were blind in Nigeria. However, surveys conducted earlier also showed that the prevalence of cataract blindness among people aged 50 and above ranged between 2.1 and 3.8 percent in Northern Nigeria and 4.1 percent in the Niger Delta.

Spotlight

With slow growth for pharmaceutical sales in developed markets, multinational companies (MNCs) have placed substantial organic and inorganic investments into emerging markets in recent years. The revenue driver at almost all MNCs remains the innovative medicines portfolio, despite some companies’diversification into generics, consumer medicines.

Related News

Innovation Pharmaceuticals grants intellectual property and commercialization rights to Fox Chase Chemical Diversity for antifungal technology

Innovation Pharmaceuticals, Fox Chase Chemical Diversity Center | July 23, 2020

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectual property and commercialization rights related to its share of their joint antifungal drug program. Both parties believe the new agreement is favorable to each, with FCCDC continuing to advance discovery and drug development, and Innovation Pharmaceuticals benefiting from potential future commercialization. Over $5 million in government grants have helped fund antifungal work conducted to date.

Read More

PCI Pharma Services Announces Global Clinical Footprint With Creation COE in Western Europe

PCI Pharma Services | July 28, 2020

PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin location, a major investment that will represent a new flagship site for customers. This is part of PCI’s global strategy to expand its clinical supply-chain network into continental Europe to complement offerings available at its UK and Ireland sites. The COE is expected to be completed in January 2021. “With this expansion, our Berlin Clinical Center of Excellence will address the needs of European and global clients,” said Brian Keesee, vice president and general manager, Global Clinical Operations and Supply, PCI Pharma Services. “Berlin is an excellent logistical hub that will serve as a proactive solution to Brexit, ensuring there are no gaps in the supply chain and our clients conducting clinical trials in all parts of Europe continue to be served.”

Read More

InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences

Prnewswire | August 24, 2020

We are very pleased that the abstract with the CONDUCT study results has been selected for oral presentation at both the UEGW and the ACG Annual Scientific Meeting", says Peter Zerhouni, CEO of InDex Pharmaceuticals. "These events are great opportunities for us to further reach the international scientific community with the successful results." UEGW is the largest scientific meeting for gastroenterologists in Europe and is this year held virtually October 11-13. The CONDUCT study will be presented on October 12 during the session "IBD: Clinical trials III" which starts at 16:30 CET. The abstract (OP117) is titled "COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL".

Read More

Spotlight

With slow growth for pharmaceutical sales in developed markets, multinational companies (MNCs) have placed substantial organic and inorganic investments into emerging markets in recent years. The revenue driver at almost all MNCs remains the innovative medicines portfolio, despite some companies’diversification into generics, consumer medicines.